Breaking boundaries: Exploring extended pembrolizumab in first-line treatment of renal cell carcinoma with axitinib-pembrolizumab combination
C. Aydogdu, Jozefina Casuscelli(LMU Klinikum), Axel S. Merseburger(Universitäres Kinderwunschzentrum Lübeck), Marco J. Schnabel(University of Regensburg), F. Roghmann, Philipp Ivanyi(Medizinische Hochschule Hannover), Katrin Schlack(Unknown), C.G. Stief, Christopher Darr(Essen University Hospital), Pia Paffenholz(University Hospital Cologne), Analena Handke, S. Tschäbitz, Viktor Grünwald(Deutsche Schmerzgesellschaft), Rafał Stelmach, S. Mandal(Bose Institute)
Cited by 0
Related Papers
Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a<i>BRCA1</i>or<i>BRCA2</i>Gene Alteration
|Journal of Clinical Oncology|2020|676
Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial
|The Lancet Oncology|2017|431
Quality of life in patients with advanced renal cell carcinoma given nivolumab versus everolimus in CheckMate 025: a randomised, open-label, phase 3 trial
|The Lancet Oncology|2016|219
Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study
|Journal of Clinical Oncology|2024|170
Genomic landscape and evolution of metastatic chromophobe renal cell carcinoma
|JCI Insight|2017|129